BACKGROUND: Pancreatic cancer is a rapidly progressive disease which is often only amenable to palliative treatment. Few patients respond to palliative chemotherapy, so surrogate markers indicating which patients are likely to respond to treatment are required. There is a well-established link between pro-inflammatory circulating cytokines and growth factors (CAF), and the development of neoplasia. Agents that may modulate these factors are of interest in developing potential novel therapeutic applications. METHODS: As part of a single-arm phase II trial in patients with advanced pancreatic cancer (APC) treated with gemcitabine and intravenous (i.v.) omega-3 rich lipid emulsion (n-3FA), serum samples were analysed for 14 CAF using a multiplex cytokine array. Baseline serum concentrations were correlated with overall (OS) and progression-free survival (PFS), and changes in concentration correlated with time and outcomes for CAF responders were analysed. RESULTS: Platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) concentrations reduced significantly with treatment over time. Low baseline interleukin (IL)-6 and -8 were correlated with improved OS. PDGF responders showed a tendency towards improved OS and FGF responders a significantly improved PFS. DISCUSSION: Treatment with gemcitabine plus i.v. n-3FA may reduce concentrations of CAF which may be associated with an improved outcome. Baseline IL-6 and -8 may be surrogate markers for outcome in patients with APC treated with this regimen.
BACKGROUND:Pancreatic cancer is a rapidly progressive disease which is often only amenable to palliative treatment. Few patients respond to palliative chemotherapy, so surrogate markers indicating which patients are likely to respond to treatment are required. There is a well-established link between pro-inflammatory circulating cytokines and growth factors (CAF), and the development of neoplasia. Agents that may modulate these factors are of interest in developing potential novel therapeutic applications. METHODS: As part of a single-arm phase II trial in patients with advanced pancreatic cancer (APC) treated with gemcitabine and intravenous (i.v.) omega-3 rich lipid emulsion (n-3FA), serum samples were analysed for 14 CAF using a multiplex cytokine array. Baseline serum concentrations were correlated with overall (OS) and progression-free survival (PFS), and changes in concentration correlated with time and outcomes for CAF responders were analysed. RESULTS: Platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) concentrations reduced significantly with treatment over time. Low baseline interleukin (IL)-6 and -8 were correlated with improved OS. PDGF responders showed a tendency towards improved OS and FGF responders a significantly improved PFS. DISCUSSION: Treatment with gemcitabine plus i.v. n-3FA may reduce concentrations of CAF which may be associated with an improved outcome. Baseline IL-6 and -8 may be surrogate markers for outcome in patients with APC treated with this regimen.
Authors: H Tsushima; N Ito; S Tamura; Y Matsuda; M Inada; I Yabuuchi; Y Imai; R Nagashima; H Misawa; H Takeda; Y Matsuzawa; S Kawata Journal: Clin Cancer Res Date: 2001-05 Impact factor: 12.531
Authors: Ali Arshad; Dhya Al-Leswas; Omer Al-Taan; James Stephenson; Matthew Metcalfe; William P Steward; Ashley R Dennison Journal: Am J Clin Oncol Date: 2013-08 Impact factor: 2.339
Authors: Marco Niedergethmann; Ralf Hildenbrand; Birgit Wostbrock; Mark Hartel; Jörg W Sturm; Axel Richter; Stefan Post Journal: Pancreas Date: 2002-08 Impact factor: 3.327
Authors: K H Baumann; F Hessel; I Larass; T Müller; P Angerer; R Kiefl; C von Schacky Journal: Arterioscler Thromb Vasc Biol Date: 1999-01 Impact factor: 8.311
Authors: Juqun Shen; Marie D Vil; Haifan Zhang; James R Tonra; Ling L Rong; Chris Damoci; Marie Prewett; Dhanvanthri S Deevi; Jessica Kearney; David Surguladze; Xenia Jimenez; Michelle Iacolina; Rajiv Bassi; Kai Zhou; Paul Balderes; Venkat R M Mangalampalli; Nick Loizos; Dale L Ludwig; Zhenping Zhu Journal: Biochem Biophys Res Commun Date: 2007-04-19 Impact factor: 3.575
Authors: Solange Valdes; Youssef W Naguib; Rick A Finch; Wallace B Baze; Christopher A Jolly; Zhengrong Cui Journal: Pharm Res Date: 2017-03-28 Impact factor: 4.200
Authors: T E Bapiro; K K Frese; A Courtin; J L Bramhall; B Madhu; N Cook; A Neesse; J R Griffiths; D A Tuveson; D I Jodrell; F M Richards Journal: Br J Cancer Date: 2014-05-29 Impact factor: 7.640
Authors: Youssef W Naguib; Dharmika Lansakara-P; Laura M Lashinger; B Leticia Rodriguez; Solange Valdes; Mengmeng Niu; Abdulaziz M Aldayel; Lan Peng; Stephen D Hursting; Zhengrong Cui Journal: Neoplasia Date: 2016-01 Impact factor: 5.715